Neoprobe In RIGScan Setback
Neoprobe shares fell 26% last week after the European MedicinesEvaluation Agency recommended that it withdraw its marketing application for RIGScan (CR49), an antibody-based imaging agent used in the surgical treatment of colorectal cancer. The EMEA said it made the decision because of additional requests for information from another regulatory body.
RIGScan is used with a probe to determine the spread of colorectal cancers, so that surgical removal of metastases can be more effective. Neoprobe president David Bupp said the company hopes to refile the application in the second quarter of 1998, and hopes for approval later that year.
The company had been counting on getting around $2 million in income from RIGScan in this financial year. It may now refile the application with new data seeking to market the antibody as an adjunct for surgical resection of primary, as well as metastatic tumor sites.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze